Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Account Payables (2022 - 2025)

Axsome Therapeutics' Change in Account Payables history spans 4 years, with the latest figure at $11.3 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 46.05% year-over-year to $11.3 million; the TTM value through Dec 2025 reached -$6.5 million, down 120.63%, while the annual FY2025 figure was -$6.5 million, 120.63% down from the prior year.
  • Change in Account Payables for Q4 2025 was $11.3 million at Axsome Therapeutics, up from -$37.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $25.8 million in Q4 2022 and bottomed at -$37.4 million in Q3 2025.
  • The 4-year median for Change in Account Payables is $7.0 million (2022), against an average of $3.3 million.
  • The largest annual shift saw Change in Account Payables surged 562.5% in 2024 before it crashed 1383.93% in 2025.
  • A 4-year view of Change in Account Payables shows it stood at $25.8 million in 2022, then tumbled by 55.04% to $11.6 million in 2023, then plummeted by 33.13% to $7.7 million in 2024, then skyrocketed by 46.05% to $11.3 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Change in Account Payables are $11.3 million (Q4 2025), -$37.4 million (Q3 2025), and $6.0 million (Q2 2025).